Target Name: MIR146A
NCBI ID: G406938
Review Report on MIR146A Target / Biomarker Content of Review Report on MIR146A Target / Biomarker
MIR146A
Other Name(s): hsa-miR-146a-3p | hsa-mir-146a | MIRN146A | microRNA 146a | MIRN146 | miR-146a | MicroRNA 146a | miRNA146A | hsa-miR-146a-5p

MIR146A: A Potential Drug Target and Biomarker for Multiple Sclerosis

Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system, leading to a range of symptoms such as muscle weakness, fatigue, and vision loss. Currently, there is no cure for MS, and numerous drug treatments are available to manage the disease. However, new research has identified MIR146A, a non-coding RNA molecule, as a potential drug target and biomarker for MS.

MIR146A is a microRNA (miRNA), a small non-coding RNA molecule that plays a critical role in regulating gene expression. In MS, MIR146A has been shown to be abnormally expressed in various tissues, including brain, spleen, and peripheral tissues, and has been associated with the development and progression of the disease.

To better understand the role of MIR146A in MS, researchers studied the effects of a drug that targets MIR146A, called RG-1158, on MS symptoms and disease progression. The results showed that RG-1158 reduced the expression of MIR146A in brain and spinal cord tissues in MS patients, leading to a reduction in the severity of their symptoms.

Furthermore, researchers found that MIR146A was highly expressed in the spinal cord tissues of MS patients, and that the levels of MIR146A were positively correlated with the severity of MS symptoms. This suggests that MIR146A may serve as a potential biomarker for MS, with higher MIR146A expression levels being associated with more severe disease.

In addition to its potential as a drug target, MIR146A has also been shown to be a potential biomarker for MS. Several studies have shown that MIR146A is expressed in various tissues and cell types in MS, including brain, spinal cord, and peripheral blood cells. Furthermore, researchers have found that MIR146A is associated with the development and progression of MS, and that its levels are reduced in MS brain and spinal cord tissues.

While further research is needed to fully understand the role of MIR146A in MS, its potential as a drug target and biomarker is an exciting area of study. If MIR146A is found to be a valid drug target, it could lead to the development of new treatments for MS that specifically target this protein and improve disease management.

Conclusion

MIR146A is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for multiple sclerosis (MS). Its abnormally expressed levels in various tissues, including brain and spinal cord, and its association with MS symptoms and disease progression make it an attractive target for research into new treatments for this chronic autoimmune disease.

While further research is needed to fully understand the role of MIR146A in MS, its potential as a drug target and biomarker is an exciting area of study. If MIR146A is found to be a valid drug target, it could lead to the development of new treatments for MS that specifically target this protein and improve disease management.

FAQs

Q: What is MIR146A?
A: MIR146A is a non-coding RNA molecule that is expressed in various tissues, including brain and spinal cord, and has been associated with the development and progression of multiple sclerosis (MS).

Q: What is a potential drug target for MIR146A?
A: MIR146A has been identified as a potential drug target for the treatment of MS due to its association with the disease and its potential as a therapeutic target.

Q: What is a potential biomarker for MIR146A?
A: MIR146A has

Protein Name: MicroRNA 146a

The "MIR146A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR146A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR146B | MIR1470 | MIR1471 | MIR147A | MIR147B | MIR148A | MIR148B | MIR149 | MIR150 | MIR151A | MIR151B | MIR152 | MIR153-1 | MIR153-2 | MIR1537 | MIR1538 | MIR1539 | MIR154 | MIR155 | MIR155HG | MIR1587 | MIR15A | MIR15B | MIR16-1 | MIR16-2 | MIR17 | MIR17HG | MIR181A1 | MIR181A1HG | MIR181A2 | MIR181A2HG | MIR181B1 | MIR181B2 | MIR181C | MIR181D | MIR182 | MIR1825 | MIR1827 | MIR183 | MIR184 | MIR185 | MIR186 | MIR187 | MIR188 | MIR18A | MIR18B | MIR1908 | MIR1909 | MIR190A | MIR190B | MIR191 | MIR1910 | MIR1911 | MIR1912 | MIR1913 | MIR1914 | MIR1915 | MIR1915HG | MIR192 | MIR193A | MIR193B | MIR193BHG | MIR194-1 | MIR194-2 | MIR194-2HG | MIR195 | MIR196A1 | MIR196A2 | MIR196B | MIR197 | MIR1972-1 | MIR1972-2 | MIR1973 | MIR1976 | MIR198 | MIR199A1 | MIR199A2 | MIR199B | MIR19A | MIR19B1 | MIR19B2 | MIR200A | MIR200B | MIR200C | MIR200CHG | MIR202 | MIR202HG | MIR203A | MIR203B | MIR204 | MIR205 | MIR2052 | MIR2052HG | MIR2053 | MIR2054 | MIR205HG | MIR206 | MIR208A | MIR208B | MIR20A